Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

#3949

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Aim(s): To evaluate the efficacy and safety of SUR plus HAIC in later-line treatment of liver metastasis-dominated HG-NEN.

Materials and methods: This is a retrospective registry of pts with unresectable or metastatic, HG-NEN treated with SUR (250 mg orally, QD) combined with HAIC (mFOLFOX6 regimen). The primary endpoint was PFS. The second endpoint were tumor response and safety.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,